Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors ; volume:24 ; number:1 ; day:7 ; month:11 ; year:2024 ; pages:1-22 ; date:12.2024
BMC cancer ; 24, Heft 1 (7.11.2024), 1-22, 12.2024
- Creator
-
Mandal, Tirtha
Gnanasegaran, Soorya
Rodrigues, Golding
Kashipathi, Shalini
Tiwari, Anurag
Dubey, Ashvini Kumar
Bhattacharjee, Sanghamitra
Manjunath, Yogendra
Krishna, Subith
Madhusudhan, M. S.
Ghosh, Maloy
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-13074-z
- URN
-
urn:nbn:de:101:1-2501252128298.550031992184
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mandal, Tirtha
- Gnanasegaran, Soorya
- Rodrigues, Golding
- Kashipathi, Shalini
- Tiwari, Anurag
- Dubey, Ashvini Kumar
- Bhattacharjee, Sanghamitra
- Manjunath, Yogendra
- Krishna, Subith
- Madhusudhan, M. S.
- Ghosh, Maloy
- SpringerLink (Online service)
Other Objects (12)
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Microenvironment‐Responsive Prodrug‐Induced Pyroptosis Boosts Cancer Immunotherapy
Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
Samd3 expressing cell contribute critically to checkpoint immunotherapy
Novel targeted therapies and immunotherapy for advanced thyroid cancers
Stimuli‐Responsive Nanocarriers as Active Enhancers of Antitumoral Immunotherapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Microenvironment‐Responsive Prodrug‐Induced Pyroptosis Boosts Cancer Immunotherapy
Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
Samd3 expressing cell contribute critically to checkpoint immunotherapy
Novel targeted therapies and immunotherapy for advanced thyroid cancers
Stimuli‐Responsive Nanocarriers as Active Enhancers of Antitumoral Immunotherapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Microenvironment‐Responsive Prodrug‐Induced Pyroptosis Boosts Cancer Immunotherapy
Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
Samd3 expressing cell contribute critically to checkpoint immunotherapy
Novel targeted therapies and immunotherapy for advanced thyroid cancers
Stimuli‐Responsive Nanocarriers as Active Enhancers of Antitumoral Immunotherapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy